Hillstream BioPharma Announces Richard M. Stone, MD as New Member to Scientific Advisory Board
Expertise in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL)

Bridgewater, New Jersey, November 18, 2020 – Hillstream BioPharma, Inc. (“Hillstream”) today announced the addition of Professor Richard M. Stone, MD, to Hillstream’s Scientific Advisory Board.

Dr. Stone brings a wealth of experience from being a Professor of Medicine at Harvard Medical School and in the Leukemia Division of the Department of Medical Oncology at Dana-Farber Cancer Institute

(DFCI). He has conducted leading-edge research in leukemia and related disorders.  Dr. Stone is Chief of Staff and Director of Translational Research in the Leukemia Division at Dana Farber Cancer Institute (DFCI).  Dr. Stone’s clinical practice focuses on patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and myeloproliferative disorders.  He has performed numerous laboratory and clinical studies and frequently participates in grand rounds worldwide. Dr. Stone’s work has been published in over 250 scientific publications, and his world-renowned research has provided new insight into genetic and environmental causes of leukemia, enabling novel cancer therapies. Dr. Stone received his Medical Degree from Harvard Medical School, completed his internal medicine residency at Brigham and Women’s Hospital and his hematology-oncology fellowship at Dana-Farber Cancer Institute.

Randy Milby, CEO of Hillstream, stated, “Dr. Stone is a great addition to our Scientific Advisory team as we progress with our product pipeline.  Dr. Stone’s extensive experience in leukemia will be an excellent and timely addition to the superb group of top-class scientists on our Scientific Advisory Board as we advance Hillstream’s product pipeline.  In addition, Dr. Stone’s relationships with leading medical institutions will benefit Hillstream as our company expands our research presence.  We look forward to working more closely with Dr. Stone.”

About Hillstream BioPharma, Inc.

Hillstream BioPharma, Inc. (“Hillstream”, the “Company”) is a clinical stage platform company developing Quatramer™. The Company is advancing lead candidates, including novel small molecules and proprietary DNA expression vectors which encode inflammatory cytokines directly into the tumor’s genome.  The lead drug candidate, HSB-1216, is in IND-enabling studies and can be developed in the clinic in 2021 for small cell lung cancer, or SCLC, and triple-negative breast cancer. The Company has achieved orphan drug designation in SCLC for HSB-1216’s payload and plans to develop other Quatramer™ based compounds with therapeutic cargoes from the product pipeline, which include DNA-based contents which hijack the tumor’s genetic code and kill the tumor from within by generating an array of cancer killing cytokines, such as tumor necrosis factor alpha or TNF-a and interleukin-2 or IL-2.  The platforms’ tunability stems from the fact that the system can be modified and adjusted to deliver single or multiple ratios of payloads in order to optimize synergistic mechanisms of action in lower doses in order to eradicate rare cancers and devastating tumors with minimal or no treatment options. For more information, please visit hillstreambio.com.

Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, as well as the risks that prior clinical and preclinical results may not be replicated. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.

Hillstream BioPharma, Inc.

Randy Milby
President & CEO
Hillstream BioPharma, Inc.
Tel: +1 302.743.2995
Email: rmilby@hillstreambio.com

Investor Contact:
Jennifer K. Zimmons, Ph.D.
Investor Relations
Zimmons International Communications
Tel: +1 917.214.3514
Email: jzimmons@zimmonsic.com

Source: Hillstream BioPharma Inc.